AB122 + TAS-120 + AB154

AB122 + TAS-120 + AB154 is an investigational combination therapy used in oncology clinical trials. AB122 (zimberelimab) is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) to inhibit immune checkpoint signaling, thereby promoting T-cell-mediated anti-tumor activity. TAS-120 (futibatinib) is an orally available, irreversible FGFR1–4 inhibitor that targets aberrant FGFR signaling pathways in cancers with FGFR genetic alterations. AB154 (domvanalimab) is a humanized monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains), an immune checkpoint, to enhance anti-tumor immunity by relieving TIGIT-mediated suppression. This combination is under investigation primarily for advanced or metastatic solid tumors, including but not limited to non-small cell lung cancer, pancreatic ductal adenocarcinoma, and other malignancies[2][4][3]. Clinical studies are evaluating the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of the combination in various cancer populations, typically as intravenous infusions (AB122, AB154) with oral TAS-120 administration[1][2][3][4].

Other names

zimberelimab + futibatinib + domvanalimab